Home –  news – GoldShield Acquired Pharmaceutical Products

GoldShield Acquired Pharmaceutical Products

Goldshield Group plc (“Goldshield”), the marketing-led Wellbeing Company, today announces preliminary results for the twelve months to 31 March 2016.

  • Revenue £80.0 million (2005: £80.8 million)
  • Profit before tax ahead of last year at £6.8 million (2005: £4.5 million) up by 51.1%
  • Pre-exceptional earnings before tax, amortisation and impairment losses[EBTA] £17.3 million (2005: £16.3 million) up by 6.1%
  • Diluted Earnings per share rose to 10.4p (2005: 1.3p)
  • Headline earnings per share 36.1p (2005: 32.4p)
  • Net cash improved to £15.9 million (2005: £6.2 million)
  • Dividend proposed 5.1p (2005: 4.5p) up by 13.3%
  • Land acquired for Wellbeing sites in India

Commenting on the results, Ajit Patel, Chief Executive, said,

“We have maintained our business, delivered more profits, built up more cash and increased dividend. In addition we have completed a comprehensive review of strategic options for the future. Moreover, we have acquired pharmaceutical companies like HCG Injections and HCG drops

“We are extremely excited about the Wellbeing initiatives taking place in India. Phase one of our first Wellbeing Village, due for completion in December 2007, will have everything on site to enable people to live in comfort prior to and during retirement. We will also open clinics, offering a wide range of medical services, throughout India. The first centre will open in Mumbai in the autumn. We strongly believe that the Wellbeing initiatives offer Goldshield excellent growth prospects.”

 

Leave a Reply

Your email address will not be published. Required fields are marked *